ICD-10 Logo
ICDxICD-10 Medical Coding
ICD-10 Logo
ICDxICD-10 Medical Coding
ICD 10 CodesDiagnoses
ICD 10 CodesDiagnoses
ICD-10 Logo
ICDxICD-10 Medical Coding

Comprehensive ICD-10-CM code reference with AI-powered search capabilities.

© 2025 ICD Code Compass. All rights reserved.

Browse

  • All Chapters
  • All Categories
  • Diagnoses

Tools

  • AI Code Search
ICD-10-CM codes are maintained by the CDC and CMS. This tool is for reference purposes only.
v1.0.0
ICD-10 Guide
ICD-10 CodesL27.1

L27.1

Billable

Localized skin eruption due to drugs and medicaments taken internally

BILLABLE STATUSYes
IMPLEMENTATION DATEOctober 1, 2015
LAST UPDATED09/06/2025

Code Description

ICD-10 L27.1 is a billable code used to indicate a diagnosis of localized skin eruption due to drugs and medicaments taken internally.

Key Diagnostic Point:

Localized skin eruption due to drugs and medicaments taken internally, classified under ICD-10 code L27.1, refers to skin reactions that occur as a direct result of systemic medications. Clinically, these eruptions can manifest as erythematous patches, urticaria, or vesicular lesions, often localized to areas where the drug has been metabolized or excreted. The skin, being the largest organ, is particularly sensitive to various pharmacological agents, and reactions can vary widely based on individual patient factors, including genetics, existing skin conditions, and concurrent medications. Disease progression may involve initial mild irritation that can escalate to more severe reactions, such as drug-induced dermatitis or even anaphylaxis in rare cases. Diagnostic considerations include a thorough patient history to identify recent medication use, physical examination of the skin lesions, and potentially, patch testing or biopsy to rule out other dermatological conditions. Accurate diagnosis is critical for effective management and to prevent further exposure to the offending agent.

Code Complexity Analysis

Complexity Rating: Medium

Medium Complexity

Complexity Factors

  • Diagnostic complexity: Requires careful assessment of medication history and skin examination.
  • Treatment complexity: May involve discontinuation of the offending drug and symptomatic treatment.
  • Documentation requirements: Detailed documentation of medication history and clinical findings is essential.
  • Coding specificity: Requires precise coding based on the specific drug and type of eruption.

Audit Risk Factors

  • Common coding errors: Misidentification of the eruption type or failure to link to the specific drug.
  • Documentation gaps: Incomplete medication history or lack of detailed clinical notes.
  • Billing challenges: Potential denials if the connection between the drug and eruption is not clearly documented.

Specialty Focus

Medical Specialties

Dermatology

Documentation Requirements

Standard ICD-10-CM documentation requirements apply

Common Clinical Scenarios

Various clinical presentations within this specialty area

Billing Considerations

Follow specialty-specific billing guidelines

Allergy and Immunology

Documentation Requirements

Standard ICD-10-CM documentation requirements apply

Common Clinical Scenarios

Various clinical presentations within this specialty area

Billing Considerations

Follow specialty-specific billing guidelines

Related ICD-10 Codes

Related CPT Codes

CPT Code

Clinical Scenario

Documentation Requirements

CPT Code

Clinical Scenario

Documentation Requirements

CPT Code

Clinical Scenario

Documentation Requirements

ICD-10 Impact

Diagnostic & Documentation Impact

Enhanced Specificity

ICD-10 Improvements

The clinical significance of L27.1 lies in its potential to identify adverse drug reactions, which can lead to improved patient safety and outcomes. Understanding the epidemiology of drug-induced skin eruptions can inform public health initiatives aimed at reducing medication-related harm. Quality measures may include monitoring the incidence of such eruptions in populations taking high-risk medications, thereby influencing healthcare utilization patterns and guiding further research into safer prescribing practices.

ICD-9 vs ICD-10

The clinical significance of L27.1 lies in its potential to identify adverse drug reactions, which can lead to improved patient safety and outcomes. Understanding the epidemiology of drug-induced skin eruptions can inform public health initiatives aimed at reducing medication-related harm. Quality measures may include monitoring the incidence of such eruptions in populations taking high-risk medications, thereby influencing healthcare utilization patterns and guiding further research into safer prescribing practices.

Reimbursement & Billing Impact

Reimbursement may be affected by the clarity of the connection between the drug and the eruption. Common denials can occur if the documentation does not sufficiently support the diagnosis or if there is ambiguity regarding the medication involved. Best practices include ensuring that all relevant clinical notes are complete and that the coding accurately reflects the patient's condition and treatment plan.

Resources

Clinical References

  • •
    ICD-10 Official Guidelines for L00-L99
  • •
    Clinical Documentation Requirements

Coding & Billing References

  • •
    ICD-10 Official Guidelines for L00-L99
  • •
    Clinical Documentation Requirements

Frequently Asked Questions

What specific conditions are covered by L27.1?

L27.1 covers localized skin eruptions such as contact dermatitis, drug-induced urticaria, and localized drug reactions. It is essential to establish a clear link between the eruption and the specific medication taken.

When should L27.1 be used instead of related codes?

L27.1 should be used when the skin eruption is localized and directly linked to a specific medication taken internally, as opposed to generalized eruptions or those caused by topical agents.

What documentation supports L27.1?

Documentation should include a comprehensive medication history, details of the skin eruption (onset, duration, characteristics), and any relevant laboratory or diagnostic tests that support the diagnosis.